U.S. Gas Utilities Stock News

NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Should First FDA-Approved Gene Therapy for Genetic Hearing Loss Require Action From Regeneron Pharmaceuticals (REGN) Investors?

Earlier this month, Regeneron Pharmaceuticals received U.S. Food and Drug Administration approval for Otarmeni, the first gene therapy for genetic hearing loss caused by OTOF gene variations, using a viral vector to deliver a working OTOF gene directly into the cochlea. This approval not only introduces a new option for patients with Otoferlin-related hearing loss, but also underscores Regeneron’s progress in applying its genetic medicine capabilities to real-world treatments. We’ll now...
NasdaqGS:NWPX
NasdaqGS:NWPXConstruction

A Look At NWPX Infrastructure (NWPX) Valuation After Record Q1 2026 Earnings Beat And Backlog

NWPX Infrastructure (NWPX) is back in focus after a first quarter 2026 earnings beat, with EPS of $1.08 versus forecasts of $0.59, a record Water Transmission Systems backlog, and strong stock price momentum. See our latest analysis for NWPX Infrastructure. The first quarter earnings surprise and record Water Transmission Systems backlog have coincided with a sharp 30 day share price return of 29.59% and a year to date share price return of 80.12%. The 1 year total shareholder return of...
NYSE:ABBV
NYSE:ABBVBiotechs

What AbbVie (ABBV)'s New IBD Data for SKYRIZI and RINVOQ Means For Shareholders

In early May 2026, AbbVie reported that shareholders voted against a proposal to require an independent board chair while the company highlighted extensive new real‑world and long‑term data for its key immunology drugs SKYRIZI and RINVOQ in inflammatory bowel disease. The combination of fresh efficacy and quality‑of‑life data for these therapies and continued conference outreach underscores how central immunology remains to AbbVie’s business profile. We’ll now examine how AbbVie’s latest...
NYSE:CL
NYSE:CLHousehold Products

Is Colgate Palmolive (CL) Offering Value After Recent Defensive Demand In Household Products?

Investors may be wondering whether Colgate-Palmolive stock is offering fair value at current levels, or if the price is already reflecting too much optimism. The stock last closed at US$88.84, with returns of 1.7% over the past week, 5.6% over the past month, 14.4% year to date, 1.6% over 1 year, 19.7% over 3 years and 19.0% over 5 years. This gives a snapshot of how the market has been pricing the company recently. Recent news around Colgate-Palmolive has focused on its position within the...
NYSE:WKC
NYSE:WKCOil and Gas

A Look At World Kinect's Valuation As Q1 Strength And 2026 EPS Upgrade Renew Investor Interest

World Kinect (WKC) has returned to focus after Q1 results reflected stronger profits in its marine and aviation segments, alongside a $75 million share repurchase and a higher full-year 2026 adjusted EPS outlook. See our latest analysis for World Kinect. The Q1 beat and higher 2026 guidance appear to be feeding into price momentum, with a 1 month share price return of 20.19% and a year to date share price return of 16.25% against a more modest 1 year total shareholder return of 4.90%. This...
NYSE:GEV
NYSE:GEVElectrical

Is It Too Late To Consider GE Vernova (GEV) After Its 156% One Year Surge?

Wondering if GE Vernova at US$1,090.53 is still offering value after a strong run, or if you are turning up late to the story. The stock has logged returns of 4.3% over the past week, 10.4% over the past month, 60.5% year to date and 156.0% over the last year, which naturally raises questions about how the current price lines up with underlying value. Recent coverage has focused on GE Vernova as a pure play in the capital goods space following its separation from General Electric, with...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

Assessing T. Rowe Price Group (TROW) Valuation After Recent Share Price Momentum

Recent performance snapshot T. Rowe Price Group (TROW) has recently drawn investor attention after a period where the stock is up about 7% over the past month and roughly 9% in the past 3 months. See our latest analysis for T. Rowe Price Group. At a share price of $102.41, T. Rowe Price Group has a 30 day share price return of 6.86% and a 1 year total shareholder return of 10.54%. This suggests recent momentum contrasts with weaker longer term results such as the 5 year total shareholder...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

Encaleret NDA, Acoramidis Progress, and Buyback Could Be A Game Changer For BridgeBio (BBIO)

In early May 2026, BridgeBio Pharma reported strong new clinical and regulatory progress, including FDA submission of encaleret for ADH1 and additional Phase 3 data for acoramidis (Attruby/BEYONTTRA) in transthyretin amyloid cardiomyopathy, alongside higher quarterly revenue and a newly authorized US$500,000,000 share repurchase program. The combination of compelling late-stage trial readouts, expanding global approvals for acoramidis, and an NDA for encaleret underscores BridgeBio’s push to...
NYSE:KOS
NYSE:KOSOil and Gas

Assessing Kosmos Energy (KOS) Valuation After Record Output And Accelerated Deleveraging

Kosmos Energy (KOS) is back in focus after reporting record first quarter production of about 74,800 boepd, accelerated net debt reduction plans, and progress on its Greater Tortue Ahmeyim and Tiberius projects. See our latest analysis for Kosmos Energy. The recent operational update comes after a steep 228.18% year to date share price return and a 74.40% 90 day share price return, while the 3 year total shareholder return has declined 53.34%. This highlights strong short term momentum...